Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 6663522Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2026 award categories
- Pharmacology
- Pathology
NIH Funding · FY2024
Linked Award Amount
$1.5M
Full award amounts, FY2024
Award Records
3
Records listing this PI
Award-Linked Rank
#9,066
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2024 award records by amount
NIH award records listing Nouri Neamati as a PI. Multi-PI records show the full award amount for context.
- 5R01CA266513-03R01Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer$515.1Kaward amount
- 5R01CA253986-03R01SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma$489.1Kaward amount
- 5R01CA272641-03R01Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer$449.1Kaward amount
Award organizations
Organizations that administered FY2024 awards listing Nouri Neamati as a PI.
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardUniversity of Michigan
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #9066
- 2025$2M Cumulative Funding
- 2025Multi-Institutional ResearchAwards at 2 institutions
- 2025R01 Grant Holder
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Nouri Neamati.